BiotechTube

KZR-616

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Polymyositis

Conditions

Polymyositis, Dermatomyositis

Trial Timeline

Nov 4, 2020 → Jun 12, 2023

NCT ID
NCT04628936

About KZR-616

KZR-616 is a phase 2 stage product being developed by Kezar Life Sciences for Polymyositis. The current trial status is completed. This product is registered under clinical trial identifier NCT04628936. Target conditions include Polymyositis, Dermatomyositis.

What happened to similar drugs?

0 of 1 similar drugs in Polymyositis were approved

Approved (0) Terminated (0) Active (1)
🔄Abatacept subcutaneous + PlaceboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04628936Phase 2Completed
NCT04039477Phase 2Withdrawn
NCT03393013Phase 1/2Completed

Competing Products

6 competing products in Polymyositis

See all competitors
ProductCompanyStageHype Score
tacrolimusAstellas PharmaPre-clinical
26
Placebo + BAF312NovartisPhase 2
27
BAF312 + PlaceboNovartisPhase 2
27
MEDI7734 + PlaceboAmgenPhase 1
29
Abatacept subcutaneous + PlaceboBristol Myers SquibbPhase 3
40
KZR-616 + PlaceboKezar Life SciencesPhase 2
25